# A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

> **NCT07658534** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 290 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** Ziresovir (AK0529)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07658534
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2028-12
- **Final completion:** 2029-01
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658534, "A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07658534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*